The 20 Best WT1-Related Wilms Tumor Syndromes Doctors Near Me in Bronx, NY

Benjamin A. Gartrell, MD, is Director, Genitourinary Malignancy Program at Montefiore and an Assistant Professor of Oncology and Urology at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2012, his expertise has been in treating genitourinary malignancies including prostate cancer, bladder cancer, renal cell cancer, and testicular cancer. He is also very active in translating science findings in collaboration with research colleagues at Einstein. In 2000, Dr. Gartrell received his Bachelor of Arts in Chemistry at the College of Wooster in Ohio. Following this, he attended the Northwestern University?s Feinberg School of Medicine, in Chicago, Illinois, where he received his Doctor of Medicine in 2005. His postgraduate training began in 2005 with an internship and residency in Internal Medicine at Case Western Reserve University, which he completed in 2008. He then completed a fellowship in Hematology/Oncology at Mount Sinai School of Medicine in 2012 and became Chief Fellow from 2010-2011. With a vast range of research interests, Dr. Gartrell focuses on translational research evaluating the significance of a novel immune checkpoint molecule in bladder cancer, evaluating the role of the autonomic nervous system in?prostate cancer, toxicities associated with anticancer therapies, and the impact of bone metastasis on patients with prostate cancer. His work has been published in a number of peer-reviewed journals, including the Journal of Clinical Oncology, Urologic Oncology, and European Urology. Dr. Gartrell also participates in community outreach to promote Prostate Cancer Awareness. Dr. Gartrell is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, Nephrectomy, and Prostatectomy.

Shabnam A. Fidvi, MD, is an Attending Physician at Advanced Imaging at Montefiore Medical Park and Associate Professor of Radiology at Albert Einstein College of Medicine. Since joining the Montefiore team, her clinical focus has been abdominal imaging, including computed tomography (CT) and ultrasound modalities, and CT oncologic imaging, with a special interest in colorectal and pancreatic malignancies. Dr. Fidvi completed her medical school training at the University of Mumbai. She began her postgraduate training in Diagnostic Radiology at the University of Mumbai, B.Y.L. Nair Charitable Hospital. Following this, she completed a residency in Diagnostic Radiology at the New York Medical College, becoming Chief Resident in 2002. Dr. Fidvi went on to pursue a fellowship in Cross-Sectional Imaging at Thomas Jefferson University Hospital. Dr. Fidvi?s research focus on oncologic imaging expands from her clinical practice. Her work has been published in numerous peer-reviewed articles. She is active in teaching medical students and radiology residents and is a participant at weekly Tumor Board Conferences at Montefiore Einstein Cancer Center. Dr. Fidvi is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, WT1-Related Wilms Tumor Syndromes, Ureterocele, and Progressive Familial Intrahepatic Cholestasis Type 3.

Robert Berkenblit, MD, FACR, is Associate Medical Director at the Montefiore Imaging Center and Associate Professor of Radiology at our Albert Einstein College of Medicine. Since joining the Montefiore team in 1996, his clinical interests include utilizing CT scans, ultrasound, and MRIs to evaluate the abdomen and pelvis, particularly the genitourinary system and the adrenal glands. He also has a special interest in utilizing an open MRI system to evaluate the abdomen and pelvis. Dr. Berkenblit is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Visceromegaly, WT1-Related Wilms Tumor Syndromes, Chronic Cough, and Ureterocele.

James McKiernan, MD, is the John K. Lattimer Professor of Urology and CEO of ColumbiaDoctors. He is also Senior Vice Dean for Clinical Affairs for Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues.For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer. Dr. Mckiernan is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy. Dr. Mckiernan is board certified in Urology. Dr. Mckiernan is currently accepting new patients.

Dr. Stein is an Associate Professor of Medical Oncology at Columbia University Medical Center. He is a recognized expert in field of genitourinary oncology – treating patients with prostate, kidney, bladder and testicular cancers. He is also a member of the Experimental Therapeutics program, investigating novel therapies across all solid tumors. In addition to providing standard therapies for the treatment of genitourinary cancers such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator initiated and industry sponsored clinical trials. Dr. Stein has a particular interest in the development of novel immune therapies for the treatment of prostate cancer, both in men with early recurrence of prostate cancer as well as in men with more advanced prostate cancer. He is also helping to lead two national trials in kidney cancer sponsored by the National Cancer Institute.Dr. Stein received his B.S. in Molecular Biophysics and Biochemistry from Yale University. He earned his medical degree at New York Medical College, receiving the graduation award in oncology for his published research. He completed a residency in internal medicine at Montefiore Medical Center, and a fellowship in Hematology and Medical Oncology at Mount Sinai Medical Center. Prior to joining Columbia University, Dr. Stein practiced genitourinary oncology for 13 years at Rutgers University and has been an author on over 60 publications including guidelines for assessing the efficacy of new drugs in prostate cancer and recommendations for the use of immunotherapy to treat prostate cancer. Dr. Stein is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), and Familial Prostate Cancer. Dr. Stein is board certified in Medical Oncology. Dr. Stein is currently accepting new patients.

Alexander I. Sankin, MD, is Professor, Urology at Montefiore Einstein. His clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer. Dr. Sankin is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Ureteroscopy.

Arie Franco, MD, PhD, is an attending radiologist at Montefiore Einstein and Associate Professor, Radiology at our Albert Einstein College of Medicine. Dr. Franco’s clinical focus centers on cardiothoracic imaging, particularly in cardiac pathology in pediatric and adult populations. He is also interested in adult congenital heart disease and chest oncology. Dr. Franco is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Pleurisy, Pleural Effusion, Emphysema, and Porencephaly.

Jana Fox is a Radiation Oncologist practicing medicine in Bronx, New York. Dr. Fox is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. She is also highly rated in 38 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Angiosarcoma, Throat Cancer, and Laryngeal Cancer.

John Amodio, MD, FACR, is Chief, Radiology and Division Lead, Pediatric Radiology at Children’s Hospital at Montefiore Einstein and Professor, Radiology at our Albert Einstein College of Medicine. Dr. Amodio has 40 years of experience in pediatric imaging. His particular interest is the use of contrast ultrasound in pediatric imaging. Dr. Amodio is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Gas Bloat Syndrome, Porencephaly, Schizencephaly, and Tracheobronchopathia Osteoplastica.

Ahmed Aboumohamed, MD is an Attending Physician and a Professor in the Department of Urology at Montefiore and our Albert Einstein College of Medicine. Dr. Aboumohamed's areas of expertise include urology, urologic oncology, minimally invasive and robotic surgery, and urologic reconstruction. Dr. Aboumohamed is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Bilateral Hydronephrosis, Bladder Cancer, Hydronephrosis, Cystectomy, and Nephrectomy.

Dr. Kara L. Watts, Associate Professor of Urology, joined the urology faculty at Montefiore in 2016. She completed a fellowship in Quality and Performance Improvement in Healthcare and an extended observership in focal ablation for prostate cancer in the UK. She serves as the Director of Quality Assurance and Improvement for the Department of Urology and leads the prostate cancer screening program. Dr. Watts is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Prostate Cancer, Kidney Stones, Muscle Invasive Bladder Cancer, Vasectomy, and Ureteroscopy.

Caroline Hwang is a Hematologist practicing medicine in Bronx, New York. Dr. Hwang is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Colorectal Cancer.

Menachem Gold is a Neuroradiologist practicing medicine in Bronx, New York. Dr. Gold is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses WT1-Related Wilms Tumor Syndromes, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Vertigo, and Aseptic and Alopecic Nodules of Scalp (AANS).

Marc Janis is a Urologist practicing medicine in Mount Vernon, New York. Dr. Janis is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 34 other conditions, according to our data. His clinical expertise encompasses Male Pseudohermaphroditism with Gynecomastia, Eunuchoidism Familial Hypogonadotropic, Testicular Failure, Ureteroscopy, and Prostatic Artery Embolization.

Joshua Chaim is a Radiologist practicing medicine in New York, New York. Dr. Chaim is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses WT1-Related Wilms Tumor Syndromes, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Ureterocele, and Prostatectomy.

Anita Price is a Pediatric Radiologist practicing medicine in New York, New York. Dr. Price is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. She is also highly rated in 28 other conditions, according to our data. Her clinical expertise encompasses Pleurisy, Pleural Effusion, WT1-Related Wilms Tumor Syndromes, Pancreaticoduodenectomy, and Orchiectomy.

James Fuqua is a Radiologist practicing medicine in New York, New York. Dr. Fuqua is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses WT1-Related Wilms Tumor Syndromes, Muscle Invasive Bladder Cancer, ALK-Positive Non-Small Cell Lung Cancer, and Lymphoid Hyperplasia.

Debra Sarasohn is a Radiologist practicing medicine in New York, New York. Dr. Sarasohn is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses WT1-Related Wilms Tumor Syndromes, Renal Cell Carcinoma (RCC), Ascites, and Thyroid Nodule.

Omer Aras is a Radiologist practicing medicine in New York, New York. Dr. Aras is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses WT1-Related Wilms Tumor Syndromes, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), and Liver Embolization.

Oguz Akin is a Radiologist practicing medicine in New York, New York. Dr. Akin is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Prostatectomy.